Johnson & Johnson Declares Crucell Offer Unconditional
22 Février 2011 - 8:40AM
Dow Jones News
U.S. pharmaceuticals company Johnson & Johnson (JNJ) said
Tuesday it completed the tender offer for Dutch biotechnology
company Crucell NV (CRXL.AE) and has declared the offer
unconditional.
MAIN FACTS:
- Johnson & Johnson declares the Offer for unconditional
- As a result, Crucell will now operate as the center for
vaccines within the Johnson & Johnson pharmaceuticals
group.
- Share Acceptance Level is 95.24% of the issued and outstanding
share capital of Crucell
- Settlement of the Offer will take place on 25 February
2011
- Remaining Shares can be tendered in a Subsequent Offering
Period ending 8 March 2011
- Johnson & Johnson intends to acquire the remaining Shares
not tendered by means of buy-out proceedings in accordance with
article 2:92a and/or 359c of the Dutch Civil Code, to be initiated
as soon as reasonably practicable under applicable rules and
regulations
- By Amsterdam Bureau, Dow Jones Newswires;
amsterdam@dowjones.com
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
Real-Time news about Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Crucell N.V. ADS